modelEnalapril

Diagram of Enalapril

Extends from Pharmacolibrary.Drugs.ATC.C.C09AA02.

Information

name:Enalapril
ATC code:C09AA02
route:oral
compartments:1
dosage:10mg
volume of distribution:124L
clearance:224ml/min
other parameters in model implementation

Enalapril is an angiotensin-converting enzyme (ACE) inhibitor used primarily for the treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction. It is an approved and widely prescribed medication for these indications.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult subjects after single oral administration.

References

  1. Tian, L, et al., & Li, Y (2011). Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clinical therapeutics 33(5) 655–663. DOI:10.1016/j.clinthera.2011.04.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21665049

  2. Ding, PY, et al., & Liao, W (2000). Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors?. Journal of human hypertension 14(3) 163–170. DOI:10.1038/sj.jhh.1000856 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10694829

  3. DiBianco, R (1986). Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Medical toxicology 1(2) 122–141. DOI:10.1007/BF03259832 PUBMED:https://pubmed.ncbi.nlm.nih.gov/3023783

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)